Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Renal Pharmacology and Lipid Metabolism
share announcement

Renal Pharmacology and Lipid Metabolism

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 6489

Special Issue Editor

Prof. Dr. Yuji Kamijo

E-Mail Website
Guest Editor
Department of Nephrology, Shinshu University Hospital, Matsumoto 390-8621, Japan
Interests: nephrology; tubule; glomerulus; lipid metabolism; renal pathology

Special Issue Information

Dear Colleagues,

The kidney is a representative organ that metabolizes various lipids, including fatty acids, cholesterol, and glycolipids. Abnormal lipid metabolism in the kidney causes various renal pathological conditions. Since lipid accumulation in the kidney due to abnormal renal lipid metabolism exerts lipotoxicity and causes organelle damage, including in the endoplasmic reticulum and mitochondria, it is an important risk factor for the development of kidney diseases. Furthermore, the kidney is a typical vascular organ and systemic dyslipidemia causes renal vascular damage, which is deeply involved in the mechanism of kidney disease progression. Elucidation of the molecular mechanism of renal and systemic dyslipidemia (and its involvement in the mechanism of kidney disease progression), as well as the establishment of evidence indicating the benefits of intervention therapy against lipotoxicity, are expected to lead to the establishment of novel kidney disease treatment strategies. In this Special Issue, we seek research papers presenting novel results regarding these issues.

Prof. Dr. Yuji Kamijo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nephrology
  • renal pharmacology
  • renal pathology
  • lipid metabolism

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 3160 KiB  
Article
Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
by Daiki Aomura, Makoto Harada, Yosuke Yamada, Takero Nakajima, Koji Hashimoto, Naoki Tanaka and Yuji Kamijo
Metabolites 2021, 11(6), 372; https://doi.org/10.3390/metabo11060372 - 9 Jun 2021
Cited by 9 | Viewed by 2952
Abstract
As classical agonists for peroxisomal proliferator-activated receptor alpha (PPARα), fibrates activate renal fatty acid metabolism (FAM) and provide renoprotection. However, fibrate prescription is limited in patients with kidney disease, since impaired urinary excretion of the drug causes serious adverse effects. Pemafibrate (PEM), a [...] Read more.
As classical agonists for peroxisomal proliferator-activated receptor alpha (PPARα), fibrates activate renal fatty acid metabolism (FAM) and provide renoprotection. However, fibrate prescription is limited in patients with kidney disease, since impaired urinary excretion of the drug causes serious adverse effects. Pemafibrate (PEM), a novel selective PPARα modulator, is mainly excreted in bile, and, thus, may be safe and effective in kidney disease patients. It remains unclear, however, whether PEM actually exhibits renoprotective properties. We investigated this issue using mice with fatty acid overload nephropathy (FAON). PEM (0.5 mg/kg body weight/day) or a vehicle was administered for 20 days to 13-week-old wild-type male mice, which were simultaneously injected with free fatty acid (FFA)-binding bovine serum albumin from day 7 to day 20 to induce FAON. All mice were sacrificed on day 20 for assessment of the renoprotective effect of PEM against FAON. PEM significantly attenuated the histological findings of tubular injury caused by FAON, increased the renal expressions of mRNA and proteins related to FAM, and decreased renal FFA content and oxidative stress. Taken together, PEM exhibits renoprotective effects through the activation and maintenance of renal FAM and represents a promising drug for kidney disease. Full article
(This article belongs to the Special Issue Renal Pharmacology and Lipid Metabolism)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

13 pages, 766 KiB  
Review
Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma
by Ion Alexandru Bobulescu, Laurentiu M. Pop, Chinnadurai Mani, Kala Turner, Christian Rivera, Sabiha Khatoon, Subash Kairamkonda, Raquibul Hannan and Komaraiah Palle
Metabolites 2021, 11(9), 608; https://doi.org/10.3390/metabo11090608 - 7 Sep 2021
Cited by 15 | Viewed by 3064
Abstract
Clear cell renal cell carcinoma is the most common and deadly type of cancer affecting the kidney, and is characterized histologically by large intracellular lipid deposits. These deposits are thought to result from lipid metabolic reprogramming occurring in tumor cells, but the exact [...] Read more.
Clear cell renal cell carcinoma is the most common and deadly type of cancer affecting the kidney, and is characterized histologically by large intracellular lipid deposits. These deposits are thought to result from lipid metabolic reprogramming occurring in tumor cells, but the exact mechanisms and implications of these metabolic alterations are incompletely understood. Obesity is an independent risk factor for clear cell renal cell carcinoma, and is also associated with lipid accumulation in noncancerous epithelial cells of the proximal tubule, where clear cell renal cell carcinoma originates. This article explores the potential link between obesity-associated renal lipid metabolic disturbances and lipid metabolic reprogramming in clear cell renal cell carcinoma, and discusses potential implications for future research. Full article
(This article belongs to the Special Issue Renal Pharmacology and Lipid Metabolism)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop